EP
CGEM icon

Essential Partners’s Cullinan Oncology CGEM Stock Holding History

Essential Partners’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.29K Sell
510
-290
-36% -$4.31K ﹤0.01% 1245
2026
Q1 		$11.4K Buy
800
+9
+1% +$116 ﹤0.01% 1192
2025
Q4 		$8.19K Buy
791
+460
+139% +$4.15K ﹤0.01% 1239
2025
Q3 		$1.96K Buy
331
+291
+728% +$2.13K ﹤0.01% 1796
2025
Q2 		$301 Buy
+40
New +$321 ﹤0.01% 1843

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Essential Partners's CGEM Position: Q2 2026 in Review

Essential Partners reduced its Cullinan Oncology (CGEM) stake by 36% in Q2 2026, selling an estimated $4.31K and leaving 510 shares worth $9.29K. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Essential Partners first reported a position in CGEM in Q2 2025 and has held it in 5 quarters since. The position peaked at $11.4K in Q1 2026. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Essential Partners held 510 shares of Cullinan Oncology worth $9.29K as of Q2 2026.
  • Essential Partners sold 290 Cullinan Oncology shares in Q2 2026, an estimated $4.31K.
  • Cullinan Oncology made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1245 holding.
  • Essential Partners first reported a position in Cullinan Oncology in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Cullinan Oncology position peaked at $11.4K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.